TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24064510

Group type: EXPERIMENTAL
Intervention: Cloxacillin + Amikacin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefotaxime + Gentamicin
Number of subjects: 90
Study: 22406323

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 176
Study: 20613777

Group type: EXPERIMENTAL
Intervention: UVR exposure in PLE patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: UVR exposure in healthy controls
Number of subjects: 24
Study: 19046249

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention directed at a healthy diet and increased physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15531318

Group type: EXPERIMENTAL
Intervention: Radiotherapy (20 Gy delivered in 5 daily fractions of 4 Gy each; 6 MV)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No radiotherapy (sham radiotherapy or observation)
Number of subjects: 88
Study: 11133599

Group type: EXPERIMENTAL
Intervention: Conventional cementing technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Modified cementing technique
Number of subjects: 120
Study: 9753893

Group type: EXPERIMENTAL
Intervention: Drivers with cardiovascular diseases (sick drivers)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Healthy drivers (control group)
Number of subjects: 419
Study: 8072721

Group type: EXPERIMENTAL
Intervention: Calcium antagonists in chronic haemodialysis patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril, verapamil, and metoprolol in 5/6 nephrectomized rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide in rats with streptozotocin-induced diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in normotensive patients with microalbuminuric diabetes or non-diabetic uraemic nephropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors in diabetic nephropathy and non-diabetic uraemic nephropathy
Number of subjects: 0
Study: 2483115

Group type: EXPERIMENTAL
Intervention: Dithranol with 2% salicylic acid (D + S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dithranol in the same base without salicylic acid (D‐S)
Number of subjects: 0
Study: 28978279

Group type: EXPERIMENTAL
Intervention: Spaced schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massed schedule
Number of subjects: 0
Study: 28375862

Group type: EXPERIMENTAL
Intervention: SBB attachments
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healing abutments
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional removable partial dentures (CRPDs)
Number of subjects: 10
Study: 26598473

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention (PE)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nonstructured group intervention (NS)
Number of subjects: 89
Study: 24092750

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 7863

Group type: EXPERIMENTAL
Intervention: Increase in Lp(a) at 1 year
Number of subjects: 7863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7863
Study: 21166722

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Triamcinolone 0.1% cream
Number of subjects: 20
Study: 18305467

Group type: EXPERIMENTAL
Intervention: Cyclosporine with adjusted dosage to maintain trough levels of 60-80 ng/ml in Group A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine with fixed dosage of 2.5 mg/kg/day in Group B
Number of subjects: 0
Study: 16597078

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (448 microg for 36 months)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Flunisolide (1,181 microg for 41 months)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (745 microg for 19 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oral corticosteroids (positive control)
Number of subjects: 103
Study: 12563621

Group type: EXPERIMENTAL
Intervention: Anthropometric measures (weight, stature, BMI, arm and calf circumference, triceps and subscapular skinfolds)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Anthropometric measures in patients with diabetes
Number of subjects: 1000
Study: 12678512

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg I.M. with 20 mg chlorpheniramine maleate (CPM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (CPM, 20 mg) I.M.
Number of subjects: 61
Study: 9411330

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 20
Study: 8409568

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 600 mg tds
Number of subjects: 136

Group type: COMPARATOR
Intervention: Diclofenac dispersible 50 mg tds
Number of subjects: 136
Study: 3954112

Group type: EXPERIMENTAL
Intervention: Oral controlled release morphine (30 mg CRM orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural morphine (4 mg morphine epidurally)
Number of subjects: 20
Study: 30839263

Group type: EXPERIMENTAL
Intervention: Video game self-training (n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional self-training (n = 11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study: 29068725

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Calf muscle performance tests
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Heel-rise height
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Achilles tendon Total Rupture Score (ATRS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physical Activity Scale (PAS)
Number of subjects: 66
Study: 26822799

Group type: EXPERIMENTAL
Intervention: Creatine augmentation of escitalopram
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo augmentation of escitalopram
Number of subjects: 52
Study: 25102385

Group type: EXPERIMENTAL
Intervention: Activity-based therapy (ABT) for 24 weeks, 9h/wk including developmental sequencing, resistance training, repetitive, patterned motor activity, and task-specific locomotor training
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Activity-based therapy (ABT)
Number of subjects: 38
Study: 22485232

Group type: EXPERIMENTAL
Intervention: PCT-guided group (study group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Prophylactic antibiotic therapy (control group)
Number of subjects: 71
Study: 20440025

Group type: EXPERIMENTAL
Intervention: TGMD-2
Number of subjects: 75
Study: 19094762

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (cECC)
Number of subjects: 40
Study: 15083597

Group type: EXPERIMENTAL
Intervention: Statin-fibrate combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin-niacin combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of cholesterol ester transfer protein and HDL therapy drugs
Number of subjects: 0
Study: 10780713

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) administered orally, twice a day from 36 weeks' gestation until labor and every 3 hours during labor.
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) group
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 372
Study: 9323348

Group type: EXPERIMENTAL
Intervention: Practice of sustained perceptual, memory and motor tasks 5 times/week for 10 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: High functioning healthy controls (n = 5) given the same tasks at difficulty levels comparable to those achieved by patients after 10 weeks of practice
Number of subjects: 22
Study: 9511601

Group type: EXPERIMENTAL
Intervention: Amalgaphase
Number of subjects: 82

Group type: COMPARATOR
Intervention: Dispersalloy (Control)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amalga 43
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Permite C
Number of subjects: 82
Study: 3512944

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.004 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.009 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.013 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physostigmine (most effective dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 11
Study: 30218228

Group type: EXPERIMENTAL
Intervention: bioactive glass‐ceramic powder/two‐step etch and rinse system
Number of subjects: 92

Group type: COMPARATOR
Intervention: control/two‐step etch and rinse system
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: bioactive glass‐ceramic powder/two‐step self‐etching system
Number of subjects: 92

Group type: COMPARATOR
Intervention: control/two‐step self‐etching system
Number of subjects: 92
Study: 29071985

Group type: EXPERIMENTAL
Intervention: Acupuncture at phenomaxillary ganglia and local acupoints (Yingxiang (LI 20, bilateral) and Yintang (EX-HN 3)) for 20 min, twice per week for 4 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral loratadine tablets for 4 weeks.
Number of subjects: 50
Study: 25344361

Group type: COMPARATOR
Intervention: PEB chemotherapy (cisplatin, etoposide, and bleomycin)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: High-dose sequential chemotherapy (HDS)
Number of subjects: 85
Study: 25034387

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100mg/d)
Number of subjects: 36
Study: 22009480

Group type: EXPERIMENTAL
Intervention: Alcohol (blood alcohol level raised to .07%) with high sexual arousal (mildly erotic film clips)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Alcohol (blood alcohol level raised to .07%) with low sexual arousal (non-erotic film clips)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Placebo with high sexual arousal (mildly erotic film clips)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Placebo with low sexual arousal (non-erotic film clips)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Water control with high sexual arousal (mildly erotic film clips)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Water control with low sexual arousal (non-erotic film clips)
Number of subjects: 117
Study: 19620014

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 103
Study: 17530973

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) stretching, performed 3 times per week for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 15593364

Group type: EXPERIMENTAL
Intervention: 23 weeks of supervised aerobic exercise
Number of subjects: 29
Study: 10730021

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (comprehensive drug therapy management program)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no access to pharmaceutical care)
Number of subjects: 210
Study: 9174297

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 20 microg + saline
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intrathecal 5% lidocaine
Number of subjects: 22
Study: 1359809

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (initial dose 170 ng.kg‐1 x min‐1, maintenance 10 ng.kg‐1 x min‐1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 34
Study: 3894971

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Standardized meal after caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standardized meal without caffeine
Number of subjects: 12
Study: 31518894

Group type: EXPERIMENTAL
Intervention: One-on-one mentorship program
Number of subjects: 438

Group type: COMPARATOR
Intervention: Basic preceptorship (Control)
Number of subjects: 438
Study: 29567432

Group type: EXPERIMENTAL
Intervention: Exposure to a negative risk-reward relationship
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Exposure to a positive risk-reward relationship
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Exposure to an uncorrelated risk-reward relationship
Number of subjects: 352
Study: 26226891

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Assist Control Ventilation (ACV)
Number of subjects: 8
Study: 25099973

Group type: EXPERIMENTAL
Intervention: Unilateral puncture group (n=36)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bilateral group (n=32)
Number of subjects: 68
Study: 23203140

Group type: EXPERIMENTAL
Intervention: 15 g soy protein and 100 mg isoflavones
Number of subjects: 180

Group type: COMPARATOR
Intervention: 15 g milk protein and 100 mg isoflavones
Number of subjects: 180

Group type: COMPARATOR
Intervention: 15 g milk protein
Number of subjects: 180
Study: 21044715

Group type: EXPERIMENTAL
Intervention: Nijmegen Falls Prevention Program (NFPP) for persons with osteoporosis (5.5 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96
Study: 19072879

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 60
Study: 16365182

Group type: EXPERIMENTAL
Intervention: Intensive surveillance strategy (including clinical evaluation, serum carcinoembryonic antigen monitoring, abdominal CT or ultrasonography, chest radiograph, and colonoscopy)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Simple surveillance strategy (clinical evaluation and serum carcinoembryonic antigen monitoring)
Number of subjects: 259
Study: 14508032

Group type: EXPERIMENTAL
Intervention: EXP
Number of subjects: 63

Group type: COMPARATOR
Intervention: CTL
Number of subjects: 63
Study: 10807441

Group type: COMPARATOR
Intervention: No postoperative pacing
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Right atrial pacing (RAP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Left atrial pacing (LAP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Biatrial pacing (BAP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Postoperative atrial pacing (any pacing strategy)
Number of subjects: 154
Study: 8836267

Group type: EXPERIMENTAL
Intervention: Piroxicam gel 15gm
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Local anaesthetic field block with 20 ml of 0.375% bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study: 1349676

Group type: EXPERIMENTAL
Intervention: olsalazine (Dipentum; 1.0 g daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: mesalazine (Asacol, with Eudragit‐S coating; 1.2 g daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: olsalazine
Number of subjects: 100

Group type: COMPARATOR
Intervention: mesalazine
Number of subjects: 100
Study: 31910201

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30992150

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg QD
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 860

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Elagolix (both dosages)
Number of subjects: 860
Study: 28315283

Group type: EXPERIMENTAL
Intervention: Swallowing Rehabilitation Protocol (SRP) including neuromuscular electrical stimulation, thermal tactile stimulation, and hyolaryngeal mobilization
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonnutritive stimulations (Control)
Number of subjects: 24
Study: 25690438

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners and nursing home staff
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 239
Study: 25688512

Group type: EXPERIMENTAL
Intervention: Everolimus in combination with octreotide LAR and metformin
Number of subjects: 43
Study: 22390264

Group type: EXPERIMENTAL
Intervention: Participants who were given the opportunity to misattribute arousal (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Participants who were not given any misattribution cues (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Participants who did not misattribute their arousal to the placebo beverage
Number of subjects: 40
Study: 19205290

Group type: EXPERIMENTAL
Intervention: Test formulation of fluticasone propionate at 200 microg/d for 4 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Innovator formulation of fluticasone propionate at 200 microg/d for 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 23
Study: 17650355

Group type: EXPERIMENTAL
Intervention: PEP bottle
Number of subjects: 20

Group type: COMPARATOR
Intervention: PEP mask
Number of subjects: 20
Study: 15635132

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 86
Study: 12396273

Group type: EXPERIMENTAL
Intervention: 4 mg (14)C‐labelled emedastine difumarate (mass balance study)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg oral emedastine difumarate b.i.d. or 4 mg o.d. for 7 consecutive days (single- and multiple-dose pharmacokinetic study)
Number of subjects: 24
Study: 10535240

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 71
Study: 7775859

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fish oil fatty acids in vitro
Number of subjects: 20
Study: 2182581

Group type: EXPERIMENTAL
Intervention: TBI/WBH (Whole Body Hyperthermia at 41.8 degrees C, initiated 10 min after TBI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: TBI/LON (Lonidamine 420 mg/m2 orally daily)
Number of subjects: 18
Study: 121884

Group type: EXPERIMENTAL
Intervention: Sodium nivimedone (200 mg thrice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31757641

Group type: EXPERIMENTAL
Intervention: Contact intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 39
Study: 29199916

Group type: EXPERIMENTAL
Intervention: Independent Medical Evaluation (IME)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IME working conditions
Number of subjects: 9

Group type: COMPARATOR
Intervention: General Practitioners (GPs)
Number of subjects: 9
Study: 26139736

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study: 23951335

Group type: EXPERIMENTAL
Intervention: Phase advance (21h cycle)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phase delay (27h cycle)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (both phase advance and phase delay)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Shorter REM sleep during the second part of the night
Number of subjects: 13
Study: 21294047

Group type: EXPERIMENTAL
Intervention: Naturalistic Action Test (planning behaviours and planning time)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Naturalistic Action Test
Number of subjects: 48
Study: 19174452

Group type: EXPERIMENTAL
Intervention: Epoetin alpha (EPOalpha) 150 UI/kg/TIW s.c. (arm 1)
Number of subjects: 218

Group type: COMPARATOR
Intervention: No EPOalpha (arm 2)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Epoetin alpha (EPOalpha)
Number of subjects: 218

Group type: COMPARATOR
Intervention: No EPOalpha
Number of subjects: 218
Study: 17101711

Group type: COMPARATOR
Intervention: 0.5 mg vitamin K1 intramuscularly (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg vitamin K1 intramuscularly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg vitamin K1 intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg vitamin K1 intramuscularly
Number of subjects: 0
Study: 15598026

Group type: EXPERIMENTAL
Intervention: Timed release glucosamine sulfate (TimeOsamine) 1,000 mg (2 x 500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Powder-filled glucosamine sulfate formulation 1,500 mg (3 x 500 mg)
Number of subjects: 12
Study: 11499735

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Not specified (high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy)
Number of subjects: 91
Study: 9269267

Group type: EXPERIMENTAL
Intervention: Copper-salicylate gel (1.5 g) applied twice daily for four weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo gel (1.5 g) applied twice daily for four weeks
Number of subjects: 116
Study: 8387151

Group type: EXPERIMENTAL
Intervention: Treatment A (2 mg E2V and 1 mg CPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment B (1 mg E2V and 0.5 mg CPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment C (2 mg E2V and 2 mg CPA)
Number of subjects: 0
Study: 2820329

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triamterene and hydrochlorothiazide (Dyazide)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29300214

Group type: EXPERIMENTAL
Intervention: 5-s static stretch (5S)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30-s static stretch (30S)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5-repetition dynamic stretch (DYN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-stretch (NS)
Number of subjects: 20
Study: 27924521

Group type: EXPERIMENTAL
Intervention: LISA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: INSURE
Number of subjects: 44
Study: 25338765

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 23543732

Group type: EXPERIMENTAL
Intervention: Palonosetron (75 mcg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 98